In the News – Cancer Vaccine Looks Good in Early Trials
Snippet from the article:
A vaccine that targets 90 percent of all cancers shows promise in early clinical trials. It seems to target the vast majority of cancers and it has produced encouraging preliminary results in phase I/II clinical trials, according to an announcement made on April 2 by the vaccine’s maker, Vaxil Biotherapeutics. The ImMucin vaccine consists of a 21 amino acid-long peptide that represents a key signaling region of Mucin 1, cell surface associated (or MUC1)—a glycoprotein expressed by 90 percent of solid and non-solid tumors.
Read the rest — A Universal Cancer Vaccine?
It’s not hair loss related, but it could prove to be more important than any development in the hair loss world. This is a very exciting announcement, even if it is very early in the grand scheme of things. This info is coming from a safety trial of just 10 patients, and there’s much more work to be done.
This is very exciting news for one of the scariest and deadliest diseases we know!
I agree Robert. Hopefully this is opening the door to closing in on a cure or cures.
It will never materialize. And it shouldn’t either. Affecting a multi billion dollar industry with a simple cure will have tremendous economic consequences.
This is more detrimental than beneficial.